SCHEMBL21175379

SCHEMBL21175379

COC(CNC(=O)Nc1c2c(nn1-c1cc(C)c(Cl)c(C)c1)CCN(C(=O)O)[C@H]2C)OC

nearest known ligand 0.35

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.35
▸ NTRK1 P04629 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21175197 0.92 ALDH1A1 (0.35) ALDH1A1NTRK1
SCHEMBL25267995 0.92 ALDH1A1 (0.35) ALDH1A1NTRK1
SCHEMBL20015354 0.90 NTRK1 (0.34) ALDH1A1NTRK1
SCHEMBL21175291 0.88 NTRK1 (0.36) ALDH1A1NTRK1
SCHEMBL20014817 0.82 NTRK1 (0.34) ALDH1A1NTRK1
SCHEMBL28952289 0.82 NTRK1 (0.34) ALDH1A1NTRK1
SCHEMBL21175270 0.81 ALDH1A1 (0.36) ALDH1A1NTRK1
SCHEMBL31424422 0.80 NTRK1 (0.31) NTRK1
SCHEMBL38651834 0.79 NTRK1 (0.34) NTRK1
SCHEMBL21192700 0.79 P2RX7 (0.33) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4349840-A2 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-04-10 — — EP disclosed
EP-3517538-B1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI PHARMACEUTICAL CO LTD (JP) 2024-03-13 — — EP disclosed
US-20230382912-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-11-30 — — US disclosed
US-11814381-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-11-14 — — US disclosed
EP-4134367-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-02-15 — — EP disclosed
US-20210017176-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2021-01-21 — — US disclosed
US-10858356-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2020-12-08 — — US disclosed
EP-3517538-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT Chugai Seiyaku Kabushiki Kaisha (JP) 2019-07-31 — — EP disclosed
US-20190225604-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2019-07-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225604-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT GLP1R, GPR119, GIPR ALDH1A1 2311/4885NTRK1 1296/4885
US-20230382912-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT GLP1R, GPR119, GIPR ALDH1A1 2311/4885NTRK1 1296/4885
US-20210017176-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT GLP1R, GPR119, GIPR ALDH1A1 2103/4885NTRK1 1086/4885
US-11814381-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect GLP1R, GPR119, GIPR ALDH1A1 2099/4885NTRK1 1098/4885
US-10858356-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect GLP1R, GPR119, GIPR ALDH1A1 2311/4885NTRK1 1296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback